并非所有闪光都是金子:非前列腺癌PSMA PET高摄取不代表[177Lu]Lu-PSMA放射性配体治疗成功
本文讨论为何非前列腺癌在PSMA PET高摄取情况下,[177Lu]Lu-PSMA放射性配体治疗的多数已发表病例肿瘤剂量仍低。以一名转移性肾细胞癌56岁男性为例,[68Ga]Ga-PSMA-11 PET/CT显示病灶高摄取,给予6.9 GBq [177Lu]Lu-PSMA-I&T后,靶病灶剂量仅0.2-0.5 Gy,无治疗效果。结论认为快速洗脱和低肿瘤剂量可能因PSMA受体位于新生血管而非肿瘤细胞,且PSMA放射性配体/受体复合物未内化;需使用半衰期更短、与靶结合驻留时间匹配的放射性核素。
要点
- 非前列腺癌PSMA PET高摄取者,[177Lu]Lu-PSMA-I&T治疗后靶病灶剂量仅0.2-0.5 Gy,无治疗效果。
- 快速洗脱和低肿瘤剂量可能与PSMA受体位于新生血管而非肿瘤细胞、复合物未内化有关。
- 作者认为需使用半衰期更短、与靶结合驻留时间匹配的放射性核素来克服早期洗脱问题。
核心结论
- 非前列腺癌中[68Ga]Ga-PSMA-11高摄取但[177Lu]Lu-PSMA-I&T肿瘤剂量低、快速洗脱,最可能因PSMA受体位于新生血管而非肿瘤细胞,且PSMA放射性配体/受体复合物未内化。
- 作者认为需使用半衰期更短、与靶结合驻留时间匹配的放射性核素来克服早期洗脱问题。
研究设计与样本
- 本文为病例报告与讨论,以一名56岁转移性肾细胞癌男性为示例。
主要发现
- [68Ga]Ga-PSMA-11 PET/CT显示该患者病灶高摄取。
- 给予一剂6.9 GBq [177Lu]Lu-PSMA-I&T,治疗后5、24和48小时行SPECT/CT及全身平面显像剂量测定。
- 靶病灶剂量仅0.2-0.5 Gy,未获得治疗效果。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The main objective is to discuss why treatment of non-prostate cancers with [177Lu]Lu-PSMA-radioligand achieved only low tumor dose in most published cases, despite high uptake on PSMA PET. We use a patient with renal cell carcinoma as an illustrative example. Furthermore, we discuss how the problem with early washout and low tumor dose might be overcome by using a radionuclide with shorter half-life, matching the target binding residence time. CASE PRESENTATION: [68Ga]Ga-PSMA-11 PET/CT of a 56-year old man with metastatic renal cell carcinoma showed high lesion uptake. One dose of 6.9 GBq [177Lu]Lu-PSMA-I&T was administrated. Post-therapy dosimetry was performed with SPECT/CT and whole-body planar imaging after 5, 24 and 48 h. Doses to target lesions were only 0.2-0.5 Gy. No treatment effect was achieved. CONCLUSION: Rapid tumor washout of [177Lu]Lu-PSMA-I&T and low tumor dose despite high uptake of [68Ga]Ga-PSMA-11 are most likely caused by localization of PSMA-receptors on neovasculature rather than on the tumor cells, and unlike in prostate cancer cells, the PSMA-RL / PSMA-receptor complex is not internalized. To overcome the problem with early washout, the use of a radionuclide with shorter half-life matching the target binding residence time will be needed.
引用
- Bogsrud TV, Engelsen O, Lu TTT, et al. All that glitters is not gold: high uptake on PSMA PET in non-prostate cancers does not mean that treatment with [177Lu]Lu-PSMA-radioligand will be successful. EJNMMI Res. 2024. PMID: 39404984. doi:10.1186/s13550-024-01156-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。